title: 1,25-dyhydroxyvitamin D3 attenuates L-DOPA-induced neurotoxicity in neural stem cells.
abstract: The neurotoxicity of levodopa (L-DOPA) on neural stem cells (NSCs) and treatment strategies to protect NSCs from this neurotoxicity remain to be elucidated. Recently, an active form of vitamin D3 has been reported to display neuroprotective properties. Therefore, we investigated the protective effect of 1,25-dyhydroxyvitamin D3 (calcitriol) on L-DOPA-induced NSC injury. We measured cell viability via the cell counting kit-8 (CCK-8) and lactate dehydrogenase (LDH) assays and Annexin V/PI staining followed by flow cytometry, cell proliferation using the BrdU and colony-forming unit (CFU) assays, cell differentiation via immunocytochemistry, the levels of free radicals via 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) staining, apoptosis via DAPI and TUNEL staining, and intracellular signaling protein expression via Western blot. Antibody microarrays were also employed to detect changes in the expression of prosurvival- and death-related proteins. Treatment of NSCs with L-DOPA reduced their viability and proliferation. This treatment also increased the levels of free radicals and decreased the expression levels of intracellular signaling proteins that are associated with cell survival. However, simultaneous exposure to calcitriol significantly reduced these effects. The calcitriol-mediated protection against L-DOPA toxicity was blocked by the phosphoinositide 3-kinase (PI3K) inhibitor LY294004. L-DOPA also inhibited the expression of Nestin and Ki-67, and co-treatment with calcitriol alleviated these effects. The expression levels of GFAP, DCX, and Tuj1 were not significantly affected by treatment with L-DOPA or calcitriol. Calcitriol protects against L-DOPA-induced NSC injury by promoting prosurvival signaling, including activation of the PI3K pathway, and reducing oxidative stress.
authors.affiliation: Department of Neurology, Hanyang University College of Medicine, Seoul, South Korea.
authors.forename: Wooyoung
authors.initials: W
authors.lastname: Jang
authors.forename: Hyun-Hee
authors.initials: HH
authors.lastname: Park
authors.forename: Kyu-Yong
authors.initials: KY
authors.lastname: Lee
authors.forename: Young Joo
authors.initials: YJ
authors.lastname: Lee
authors.forename: Hee-Tae
authors.initials: HT
authors.lastname: Kim
authors.forename: Seong-Ho
authors.initials: SH
authors.lastname: Koh
mesh_terms: D000818:Animals; D002117:Calcitriol / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D000089662:Doublecortin Protein; D007980:Levodopa / Q000037:antagonists & inhibitors / Q000633:toxicity*; D058953:Neural Stem Cells / Q000187:drug effects* / Q000502:physiology; D018696:Neuroprotective Agents / Q000494:pharmacology*; D051381:Rats
chemical_list: C000714848:Dcx protein, rat; D000089662:Doublecortin Protein; D018696:Neuroprotective Agents; D007980:Levodopa; D002117:Calcitriol
references.citation: Neurochem Res. 2004 Dec;29(12):2207-14
references.pmid: 15672541
references.citation: J Neurol. 2002 Sep;249 Suppl 2:II19-24
references.pmid: 12375059
references.citation: Neurosci Lett. 2009 Oct 25;462(3):213-8
references.pmid: 19596403
references.citation: Curr Opin Neurol. 2012 Aug;25(4):433-47
references.pmid: 22691758
references.citation: Behav Brain Res. 2005 Feb 28;157(2):299-308
references.pmid: 15639181
references.citation: Neurology. 2011 Oct 11;77(15):1420-6
references.pmid: 21917769
references.citation: Prog Neurobiol. 2011 Sep 1;94(4):389-407
references.pmid: 21723913
references.citation: Brain Res. 1997 Nov 28;777(1-2):202-9
references.pmid: 9449429
references.citation: J Neurochem. 2009 Oct;111(1):90-100
references.pmid: 19650875
references.citation: Nat Neurosci. 2004 Jul;7(7):726-35
references.pmid: 15195095
references.citation: J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42
references.pmid: 16222436
references.citation: J Neurol. 2002 Oct;249 Suppl 3:III/33-5
references.pmid: 12522570
references.citation: Brain Res. 2005 Nov 30;1063(2):180-6
references.pmid: 16257392
references.citation: J Chem Neuroanat. 2005 Jan;29(1):21-30
references.pmid: 15589699
references.citation: J Neurosci Res. 2006 May 15;83(7):1179-89
references.pmid: 16521124
references.citation: BMC Med. 2012 Jan 04;10:1
references.pmid: 22216957
references.citation: J Neurochem. 2009 Nov;111(4):1042-50
references.pmid: 19765187
references.citation: J Clin Invest. 1995 Jun;95(6):2458-64
references.pmid: 7769091
references.citation: J Neurosci. 2002 Aug 1;22(15):6639-49
references.pmid: 12151543
references.citation: Brain Res. 2000 Feb 28;857(1-2):71-7
references.pmid: 10700554
references.citation: Regen Med. 2006 Jan;1(1):15-28
references.pmid: 17465817
references.citation: J Pharmacol Exp Ther. 2003 Feb;304(2):792-800
references.pmid: 12538835
references.citation: Mov Disord. 2007 Mar 15;22(4):461-8
references.pmid: 17230473
references.citation: Neuroreport. 2012 Dec 5;23(17):989-94
references.pmid: 23114623
references.citation: Brain Res. 2011 Jan 25;1370:53-63
references.pmid: 21075093
references.citation: PLoS One. 2012;7(1):e29959
references.pmid: 22242193
references.citation: J Neurol Sci. 2006 Jan 15;240(1-2):31-6
references.pmid: 16219327
references.citation: Toxicology. 2009 Nov 30;265(3):80-6
references.pmid: 19786063
references.citation: FEBS Lett. 2009 May 6;583(9):1505-10
references.pmid: 19362551
references.citation: Trends Endocrinol Metab. 2002 Apr;13(3):100-5
references.pmid: 11893522
references.citation: Cell Mol Biol (Noisy-le-grand). 1997 Jun;43(4):543-8
references.pmid: 9220147
references.citation: Ann Neurol. 2005 Jul;58(1):31-40
references.pmid: 15912513
references.citation: J Neurosci. 2001 Jan 1;21(1):98-108
references.pmid: 11150325
references.citation: J Neurol. 2004 Sep;251 Suppl 6:VI/44-6
references.pmid: 15675725
references.citation: J Neurosci Res. 2000 Oct 1;62(1):112-9
references.pmid: 11002293
references.citation: Neurotherapeutics. 2011 Oct;8(4):539-48
references.pmid: 21901584
references.citation: Neurology. 2011 Oct 11;77(15):1416-7
references.pmid: 21917774
references.citation: Nutr Rev. 2008 Oct;66(10 Suppl 2):S116-24
references.pmid: 18844838
references.citation: J Biol Chem. 2003 Jul 25;278(30):28089-100
references.pmid: 12738794
references.citation: J Bone Miner Res. 2011 Dec;26(12):2991-3000
references.pmid: 21898591
references.citation: Nutrients. 2013 Jun 18;5(6):2206-21
references.pmid: 23778150
references.citation: Science. 2000 Oct 27;290(5492):767-73
references.pmid: 11052933
references.citation: Toxicology. 2008 May 21;247(2-3):112-8
references.pmid: 18387727
references.citation: Life Sci. 2002 Nov 29;72(2):185-98
references.pmid: 12417252
references.citation: Mol Cell Neurosci. 2003 Jul;23(3):414-26
references.pmid: 12837625
references.citation: Clin Neuropharmacol. 2002 Mar-Apr;25(2):89-96
references.pmid: 11981235
references.citation: Ann Neurol. 1994 Aug;36(2):206-14
references.pmid: 7914399
references.citation: J Neurochem. 2003 Jun;85(6):1443-54
references.pmid: 12787064
references.citation: FEBS Lett. 1999 Aug 20;457(1):53-6
references.pmid: 10486562
references.citation: Brain Res Mol Brain Res. 1992 Apr;13(3):239-50
references.pmid: 1317496
references.citation: Brain Res. 2001 Jun 15;904(1):67-75
references.pmid: 11516412
references.citation: Neuroreport. 1999 Feb 25;10(3):557-61
references.pmid: 10208589
references.citation: Dev Neurosci. 2000;22(1-2):56-67
references.pmid: 10657698
references.citation: Arch Neurol. 2010 Jul;67(7):808-11
references.pmid: 20625085
references.citation: Arch Neurol. 2011 Mar;68(3):314-9
references.pmid: 21403017
references.citation: Exp Neurol. 2010 Jun;223(2):267-81
references.pmid: 19699201
references.citation: J Neurosci Res. 2000 Nov 1;62(3):374-82
references.pmid: 11054806
references.citation: J Neurosci. 2003 Oct 15;23(28):9357-66
references.pmid: 14561863
references.citation: Ann Neurol. 2008 Dec;64 Suppl 2:S47-55
references.pmid: 19127579
references.citation: Neurotoxicology. 2014 Jul;43:102-109
references.pmid: 24631315